Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18805855 | 0.91 | PDK2 (0.38) | TOP1PDK2ALDH1A1MEN1KMT2A | |
| SCHEMBL1672627 | 0.86 | APP (0.44) | ALDH1A1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL29185539 | 0.82 | TOP1 (0.44) | TOP1PDK2ALDH1A1MEN1KMT2A | |
| SCHEMBL29589374 | 0.81 | CA1 (0.50) | ALDH1A1MAPTKDM4ETDP1CA1 | |
| SCHEMBL2544530 | 0.81 | CA1 (0.50) | ALDH1A1MAPTKDM4ETDP1CA1 | |
| SCHEMBL19659902 | 0.80 | TOP1 (0.46) | TOP1PDK2ALDH1A1MEN1KMT2A | |
| SCHEMBL29670206 | 0.80 | CA1 (0.48) | ALDH1A1MAPTKDM4ETDP1CA1 | |
| SCHEMBL29492107 | 0.77 | ALDH1A1 (0.30) | ALDH1A1RAB9A | |
| SCHEMBL333685 | 0.77 | ALDH1A1 (0.30) | ALDH1A1RAB9A | |
| SCHEMBL646868 | 0.77 | MYC (0.42) | PDK2ALDH1A1TDP1HTR7CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531695-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICAL, INC (US) | 2009-05-12 | — | — | US | claimed |
| US-20070129392-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | claimed |
| US-20070078189-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2007-04-05 | — | — | US | claimed |
| EP-1636160-A4 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2006-09-27 | — | — | EP | claimed |
| EP-1636160-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | Auspex Pharmaceuticals (US) | 2006-03-22 | — | — | EP | claimed |
| WO-2005108338-A1 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-11-17 | — | — | WO | claimed |
| WO-2005000233-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-01-06 | — | — | WO | claimed |
| US-11744152-B2 | Benzimidazo[1,2-a]benzimidazole derivatives for electronic applications | UDC IRELAND LIMITED (IE) | 2023-08-29 | — | — | US | disclosed |
| US-20170331054-A1 | LUMINESCENT DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES | UDC IRELAND LTD (IE) | 2017-11-16 | — | — | US | disclosed |
| US-9806270-B2 | 4H-imidazo[1,2-a]imidazoles for electronic applications | UDC IRELAND LIMITED (IE) | 2017-10-31 | — | — | US | disclosed |
| US-20170244051-A1 | Benzimidazo[1,2-a]Benzimidazole Derivatives for Electronic Applications | UDC IRELAND LTD (IE) | 2017-08-24 | — | — | US | disclosed |
| US-20170237020-A1 | Electroluminescent Imidazo-Quinoxaline Carbene Metal Complexes | BASF SE (DE) | 2017-08-17 | — | — | US | disclosed |
| US-9673408-B2 | Luminescent diazabenzimidazole carbene metal complexes | UDC IRELAND LIMITED (IE) | 2017-06-06 | — | — | US | disclosed |
| US-7468462-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2008-12-23 | — | — | US | disclosed |
| US-20070129392-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070078189-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2007-04-05 | — | — | US | disclosed |
| EP-1636160-A4 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2006-09-27 | — | — | EP | disclosed |
| EP-1636160-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | Auspex Pharmaceuticals (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005108338-A1 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005000233-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170331054-A1 | LUMINESCENT DIAZABENZIMIDAZOLE CARBENE METAL COMPLEXES | OCIAD1, OCIAD2, CACNA1D | TOP1 4211/4885PDK2 736/4885ALDH1A1 1819/4885 |
| US-20070078189-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | GPR119, IGF1R, CCNE2 | TOP1 4077/4885PDK2 89/4885ALDH1A1 463/4885 |
| US-11744152-B2 | Benzimidazo[1,2-a]benzimidazole derivatives for electronic applications | PAICS, EIF4A1, ECI1 | TOP1 2116/4885PDK2 43/4885ALDH1A1 122/4885 |
| US-20170237020-A1 | Electroluminescent Imidazo-Quinoxaline Carbene Metal Complexes | OCIAD1, OCIAD2, OXER1 | TOP1 2709/4885PDK2 626/4885ALDH1A1 1713/4885 |
| US-20070129392-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | IGF1R, INSR, BRCA1 | TOP1 4195/4885PDK2 86/4885ALDH1A1 826/4885 |
| US-20170244051-A1 | Benzimidazo[1,2-a]Benzimidazole Derivatives for Electronic Applications | PAICS, EIF4A1, ECI1 | TOP1 2095/4885PDK2 33/4885ALDH1A1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.